Results 71 to 80 of about 1,204 (125)

Case Report: A case of anti-mGluR1 antibody-associated encephalitis treated with efgartigimod combined with rituximab. [PDF]

Front Immunol
Liu J, Zhu W, Gao L, Zhao C.
europepmc   +1 more source

Efgartigimod as adjunctive therapy for immunotherapy-dependent autoimmune diencephalitis: A case report. [PDF]

Medicine (Baltimore)
Li C, Yin X, Jia M, Shao J, Cui L.
europepmc   +1 more source

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+). [PDF]

Front Neurol
Meisel A, Antozzi C, Bhavaraju-Sanka R, De Bleecker JL, Huang WY, Jimenez RH, Verhamme FM, Jiang M, Liu L, Korobko D, Kostera-Pruszczyk A, Utsugisawa K, Verschuuren JJGM, Vu T, Wiendl H, Howard JF.   +15 more
europepmc   +1 more source

A case report of sequential efgartigimod and rituximab treatment for tSNMG. [PDF]

Front Immunol
Xie H, Pan TT, Zhang L.
europepmc   +1 more source

Prospective study of efgartigimod in severe myasthenia gravis exacerbations requiring ventilatory or enteral support. [PDF]

J Neuromuscul Dis
Shelly S, Rosenberg A, Zoabi M, Makhoul S, Ramon-Gonen R, Wolfe GI.   +5 more
europepmc   +1 more source

Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database. [PDF]

Front Neurol
Narayanaswami P, Smith AG, Bhavaraju-Sanka R, Qi C, Jefferson M, Aldridge J, Heerlein K, Gelinas D, Dhingra M, Menon RR, Sato M, Wolfe GI.   +11 more
europepmc   +1 more source

FcRn Inhibition in Autoantibody-Mediated Autoimmune Diseases: From Broad Immunosuppression to Precision IgG Modulation. [PDF]

Mediterr J Rheumatol
Chrousos GP, Skopouli FN, Moutsopoulos HM.   +2 more
europepmc   +1 more source

Efgartigimod-alfa therapy in acetylcholine receptor antibody myasthenia gravis: Romanian experience. [PDF]

Front Neurol
Grecu N, Mihalache OA, Davidescu EI, Bălașa R, Simu M, Văcăraș V, Vodă IM, Mușuroi AI, Ene AM, Petrescu DM, Mitu CE, Furnică L, Cornea A, Homorodean R, Vîlciu C, Tiu C.   +15 more
europepmc   +1 more source

Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report. [PDF]

Front Immunol
Li K, Hu J, Gan Z, Chen J, Tian Y, Luo R, Qi X.   +6 more
europepmc   +1 more source

Steroid-Sparing Effect of Efgartigimod in Generalized Myasthenia Gravis: Study Protocol for a Single-Arm, Open-Label Clinical Trial. [PDF]

Neurol Ther
Suzuki T, Fujimaki M, Ohuchi S, Hosaka T, Shioya A, Saiki S.   +5 more
europepmc   +1 more source